Glibcla MP 5mg/500mg/15mg Tablet is a fixed-dose combination medication containing Glibenclamide (5mg), Metformin (500mg), and Pioglitazone (15mg), indicated for the management of type 2 diabetes mellitus. This combination leverages the complementary mechanisms of action of its components to achieve optimal glycemic control. Glibenclamide, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer primarily in adipose tissue, muscle, and the liver by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ). The combined effect of these agents addresses multiple pathophysiological defects in type 2 diabetes, including insulin resistance and impaired insulin secretion. Glibcla MP is indicated for patients inadequately controlled on monotherapy or dual therapy and should be used alongside diet and exercise. Caution is advised in patients with hepatic or renal impairment, heart failure, or risk factors for lactic acidosis. Regular monitoring of blood glucose, liver function, and hematologic parameters is recommended. This combination therapy should be prescribed and adjusted by healthcare professionals based on individual patient response and tolerability.